021-51111890
购物车（）
sales@molnova.cn
GSK1838705A
CAS No. 1116235-97-2
GSK1838705A ( GSK 1838705A;GSK-1838705A )
产品货号. M10424 CAS No. 1116235-97-2
GSK1838705A is a potent, specific inhibitor of IGF-IR and insulin receptor (IR) with IC50 of 2.0 and 1.6 nM.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ￥389 | 有现货 |
|
| 5MG | ￥624 | 有现货 |
|
| 10MG | ￥1077 | 有现货 |
|
| 25MG | ￥2268 | 有现货 |
|
| 50MG | ￥4099 | 有现货 |
|
| 100MG | 获取报价 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称GSK1838705A
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述GSK1838705A is a potent, specific inhibitor of IGF-IR and insulin receptor (IR) with IC50 of 2.0 and 1.6 nM.
-
产品描述GSK1838705A is a potent, specific inhibitor of IGF-IR and insulin receptor (IR) with IC50 of 2.0 and 1.6 nM, also is a potent inhibitor of ALK with IC50 of 0.5 nM; display excellent kinase selectivity on a panel of 224 unique protein kinases with only 7 additional kinases to be inhibited by >50% at 0.3 uM; inhibits a panel of cell lines derived from solid and hematologic tumors with IC50 of 20 nM-8 uM (NCI-H929 IC50=197 nM); causes complete regression of ALK-dependent tumors, retards the growth of human tumor xenografts in vivo with minimal effects on glucose homeostasis.
-
同义词GSK 1838705A;GSK-1838705A
-
通路Angiogenesis
-
靶点ALK
-
受体ALK;IGF-1R;InsulinReceptor;JNK3;RSK1
-
研究领域Cancer
-
适应症——
化学信息
-
CAS Number1116235-97-2
-
分子量532.57
-
分子式C27H29FN8O3
-
纯度>98% (HPLC)
-
溶解度10 mM in DMSO
-
SMILESO=C(NC)C1=C(F)C=CC=C1NC2=C3C(NC=C3)=NC(NC4=CC5=C(C=C4OC)CCN5C(CN(C)C)=O)=N2
-
化学全称Benzamide, 2-[[2-[[1-[2-(dimethylamino)acetyl]-2,3-dihydro-5-methoxy-1H-indol-6-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]-6-fluoro-N-methyl-
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Sabbatini P, et al. Mol Cancer Ther. 2009 Oct;8(10):2811-20.
2. Zhou F, et al. Onco Targets Ther. 2015 Apr 10;8:753-60.
3. Refolo MG, et al. Oncotarget. 2017 Sep 30;8(61):103465-103476.
4. Kelleher FC, et al. Eur J Cancer. 2010 Sep;46(13):2357-68.
2. Zhou F, et al. Onco Targets Ther. 2015 Apr 10;8:753-60.
3. Refolo MG, et al. Oncotarget. 2017 Sep 30;8(61):103465-103476.
4. Kelleher FC, et al. Eur J Cancer. 2010 Sep;46(13):2357-68.
产品手册
关联产品
-
ASP3026
ASP3026 is a potent small molecule ALK inhibitor with IC50 of 3.5, 10, 5.4 and 6.8 nM for wt ALK, ALK F1174L, ALK R1275Q and NPM1-ALK, respectively.
-
GSK1838705A
GSK1838705A is a potent, specific inhibitor of IGF-IR and insulin receptor (IR) with IC50 of 2.0 and 1.6 nM.
-
Lu AF21934
Lu AF21934 is a brain-penetrant and selective mGlu4 receptor positive allosteric modulator (IC50: 500 nM, human).
